<code id='8FF3D20B27'></code><style id='8FF3D20B27'></style>
    • <acronym id='8FF3D20B27'></acronym>
      <center id='8FF3D20B27'><center id='8FF3D20B27'><tfoot id='8FF3D20B27'></tfoot></center><abbr id='8FF3D20B27'><dir id='8FF3D20B27'><tfoot id='8FF3D20B27'></tfoot><noframes id='8FF3D20B27'>

    • <optgroup id='8FF3D20B27'><strike id='8FF3D20B27'><sup id='8FF3D20B27'></sup></strike><code id='8FF3D20B27'></code></optgroup>
        1. <b id='8FF3D20B27'><label id='8FF3D20B27'><select id='8FF3D20B27'><dt id='8FF3D20B27'><span id='8FF3D20B27'></span></dt></select></label></b><u id='8FF3D20B27'></u>
          <i id='8FF3D20B27'><strike id='8FF3D20B27'><tt id='8FF3D20B27'><pre id='8FF3D20B27'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:comprehensive    Page View:137
          Adobe

          Acadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial. 

          The negative outcome of the Phase 3 study represents a setback in the company’s efforts to expand the use of Nuplazid into the treatment of schizophrenia. The medicine is currently approved to treat hallucinations and delusions associated with Parkinson’s disease psychosis.

          advertisement

          “We are disappointed the trial did not meet its primary endpoint given the significant unmet need in patients with negative symptoms of schizophrenia,” said Acadia CEO Steve Davis, in a statement. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more
          A new drug could help frostbite victims avoid its ravages
          A new drug could help frostbite victims avoid its ravages

          JonCherry/GettyImagesTwodaysafterhisrighthandfroze,HartBeznerrealizedforthefirsttimethathemightlosei

          read more
          At least 13 dead in Texas as scorching temps continue
          At least 13 dead in Texas as scorching temps continue

          1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

          read more

          Medicare Advantage enrollment grows 7.1% to 33.4 million people

          PabloMartinezMonsivais/APRoughly33.4millionadultsolderthan65andpeoplewithdisabilitieswereenrolledina